AbbVie (NYSE:ABBV) Releases FY 2026 Earnings Guidance

AbbVie (NYSE:ABBV) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 14.370-14.570 for the period, compared to the consensus estimate of 14.260. The company issued revenue guidance of -, compared to the consensus revenue estimate of $67.1 billion.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of recent analyst reports. Guggenheim increased their price target on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. UBS Group reiterated a “neutral” rating on shares of AbbVie in a report on Tuesday, January 13th. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a report on Tuesday, November 4th. Finally, Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $251.17.

AbbVie Stock Performance

Shares of NYSE ABBV traded down $15.54 during mid-day trading on Wednesday, reaching $210.12. The company had a trading volume of 4,163,092 shares, compared to its average volume of 7,063,181. The company has a market capitalization of $371.37 billion, a price-to-earnings ratio of 159.92, a PEG ratio of 0.93 and a beta of 0.35. The stock has a fifty day moving average of $224.20 and a two-hundred day moving average of $219.16. AbbVie has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, missing the consensus estimate of $3.37 by ($0.66). AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. During the same quarter last year, the business posted $2.16 earnings per share. The business’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS. Sell-side analysts forecast that AbbVie will post 12.31 earnings per share for the current fiscal year.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 underlying results beat expectations: non‑GAAP EPS of $2.71 and revenue of ~$16.62B topped consensus, showing continued top‑line momentum. AbbVie Non‑GAAP EPS of $2.71 beats by $0.06
• Positive Sentiment: Management raised 2026 adjusted EPS guidance to $14.37–$14.57, above Street estimates, citing strong demand for newer immunology drugs. AbbVie forecasts 2026 profit above estimates
• Positive Sentiment: Immunology portfolio remains the growth engine: Skyrizi and Rinvoq posted strong double‑digit gains, offsetting much of Humira’s decline. AbbVie Revenue Rises on Immunology Growth
• Neutral Sentiment: Regulatory progress: AbbVie filed for Rinvoq in vitiligo (FDA & EMA), a potential future revenue stream but not immediate. AbbVie Submits Regulatory Applications for Rinvoq in Vitiligo
• Negative Sentiment: Segment softness: oncology revenue and aesthetics (including parts of Botox/Juvéderm) showed declines, which reduce confidence in near‑term diversification. AbbVie (ABBV) Stock: Why Shares Are Falling
• Negative Sentiment: Investor reaction to accounting items and one‑time charges: reported results included IPR&D and milestone impacts and differences between GAAP and adjusted EPS that may have clouded the beat. AbbVie Reports Full‑Year and Fourth‑Quarter 2025 Financial Results
• Negative Sentiment: Reputational/operational note: a veteran employee has publicly accused AbbVie of sidelining older staff — a negative headline but likely secondary to financial drivers. Veteran AbbVie worker accuses company of sidelining her

Institutional Investors Weigh In On AbbVie

Several institutional investors have recently made changes to their positions in ABBV. Paces Ferry Wealth Advisors LLC increased its holdings in AbbVie by 3.0% in the third quarter. Paces Ferry Wealth Advisors LLC now owns 2,303 shares of the company’s stock worth $533,000 after buying an additional 67 shares during the last quarter. Brogan Financial Inc. lifted its stake in AbbVie by 2.5% in the third quarter. Brogan Financial Inc. now owns 3,090 shares of the company’s stock valued at $715,000 after acquiring an additional 74 shares during the last quarter. Rakuten Securities Inc. grew its position in AbbVie by 26.5% in the second quarter. Rakuten Securities Inc. now owns 368 shares of the company’s stock worth $68,000 after acquiring an additional 77 shares in the last quarter. Yukon Wealth Management Inc. increased its stake in shares of AbbVie by 4.8% during the 3rd quarter. Yukon Wealth Management Inc. now owns 1,693 shares of the company’s stock worth $392,000 after purchasing an additional 77 shares during the last quarter. Finally, Parvin Asset Management LLC increased its stake in shares of AbbVie by 2.4% during the 3rd quarter. Parvin Asset Management LLC now owns 4,862 shares of the company’s stock worth $1,126,000 after purchasing an additional 112 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.